Actively Recruiting
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Led by Tasca Therapeutics · Updated on 2026-02-18
150
Participants Needed
13
Research Sites
179 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of cancer in patients with advanced cancer * What medical problems do participants have when taking CP-383 Researchers will test CP-383 in all kinds of cancers at various dose levels to determine what the best dose is to study further. Researchers will also see if certain cancers that have gene mutations respond better to CP-383 Participants will: * Take CP-383 every day by mouth until the researcher learns whether CP-383 is helping slow or reduce the cancer growth * Visit the clinic weekly for the first 6 weeks for checkups and tests * Visit the clinic every 3 weeks thereafter for checkups and tests
CONDITIONS
Official Title
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Measurable or non-measurable cancer suitable for assessing changes
- Not eligible for or unable to take standard cancer therapies
- Availability of tumor tissue for lab testing or willingness to have a safe tumor biopsy
- Diagnosed with locally advanced, recurrent, or metastatic incurable disease
- Part 1: Any solid tumor except brain cancer that has progressed and standard therapy is no longer effective or too toxic
- Part 1: Specific advanced metastatic tumors including colorectal, small cell lung, head and neck, non-small cell lung, pancreatic, bladder cancers; some with specific gene mutations
- Part 1: Selected solid tumors (except brain cancers) with specific gene mutations
- Part 2: Specific advanced metastatic tumors including colorectal, small cell lung, head and neck cancers; some with specific gene mutations
- Part 2: Selected solid tumors (except brain cancers) with specific gene mutations
- Adequate blood and urine laboratory tests
- Women and men of childbearing potential using adequate contraception
- Provides written informed consent
- Willing to comply with study protocol requirements
You will not qualify if you...
- Unable to swallow pills
- Known history of HIV, HCV, or HBV unless cured or controlled with undetectable viral load
- Active tumor in the brain
- Clinically significant liver disease
- Significant gastrointestinal diseases
- History of other cancer within past 5 years except certain likely cured cancers
- Significant cardiac disease
- Other uncontrolled diseases that could make drug unsafe
- Pregnant or lactating females
- Recent exposure to certain anti-cancer or other drugs before study start
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 13 locations
1
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, United States, 80218
Actively Recruiting
2
Florida Cancer Specialists-Lake Nona
Orlando, Florida, United States, 32827
Actively Recruiting
3
START Midwest
Grand Rapids, Michigan, United States, 49546
Actively Recruiting
4
Washington University
St Louis, Missouri, United States, 63110
Actively Recruiting
5
Nebraska Cancer Specialists
Omaha, Nebraska, United States, 68130
Actively Recruiting
6
Carolina BioOncology Institute
Huntersville, North Carolina, United States, 28078
Actively Recruiting
7
Cleveland Clinic
Cleveland, Ohio, United States, 44195
Actively Recruiting
8
Taylor Cancer Research Center
Maumee, Ohio, United States, 43537
Actively Recruiting
9
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
10
NEXT Oncology - Dallas
Dallas, Texas, United States, 75039
Actively Recruiting
11
START San Antonio
San Antonio, Texas, United States, 78229
Actively Recruiting
12
START Mountain Region
West Valley City, Utah, United States, 84119
Actively Recruiting
13
NEXT Virginia
Fairfax, Virginia, United States, 22031
Actively Recruiting
Research Team
T
Tasca Therapeutics
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
10
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here